We are live on ! Find out more
IMVT icon

Immunovant
IMVT

133 hedge funds and large institutions have $980M invested in Immunovant in 2022 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 53 increasing their positions, 28 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,504% more call options, than puts

Call options by funds: $8.87M | Put options by funds: $246K

400% more funds holding in top 10

Funds holding in top 10: 1 → 5 (+4)

312% more capital invested

Capital invested by funds: $238M → $980M (+$742M)

117% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 18

89% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 28

19% more funds holding

Funds holding: 112 → 133 (+21)

7.16% more ownership

Funds ownership: 36.59% → 43.75% (+7.2%)

Holders
133
Holders Change
+21
Holders Change %
+18.75%
% of All Funds
2.14%
Holding in Top 10
5
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+400%
% of All Funds
0.08%
New
39
Increased
53
Reduced
28
Closed
18
Calls
$8.87M
Puts
$246K
Net Calls
+$8.62M
Net Calls Change
+$6.06M

Top Buyers

1
LGM
Logos Global Management
California
+$39.7M
2
BI
BVF Inc
California
+$32.2M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$31.3M
4
State Street
State Street
Massachusetts
+$28.1M
5
CAC
Cowen and Company
New York
+$15.7M

Top Sellers

1
AGM
Alpine Global Management
New York
-$35.9M
2
EAM
Eventide Asset Management
Massachusetts
-$21.1M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$19.3M
4
WP
Woodline Partners
California
-$11.9M
5
OCA
Octagon Capital Advisors
New York
-$3.23M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$6.86M +$1.03M +81,679 +27%
Two Sigma Advisers
27
Two Sigma Advisers
New York
$6.76M +$499K +39,600 +12%
Balyasny Asset Management
28
Balyasny Asset Management
Illinois
$6.67M +$2.8M +222,272 +145%
Goldman Sachs
29
Goldman Sachs
New York
$6.59M +$3.78M +300,179 +422%
Two Sigma Investments
30
Two Sigma Investments
New York
$6.34M +$1.24M +98,470 +38%
Renaissance Technologies
31
Renaissance Technologies
New York
$6.11M -$106K -8,400 -2%
N
32
Nuveen
North Carolina
$5.75M +$1.83M +145,490 +82%
Jane Street
33
Jane Street
New York
$5.66M +$3.81M +302,965 +1,881%
D.E. Shaw & Co
34
D.E. Shaw & Co
New York
$5.3M +$3.76M +298,470 New
T. Rowe Price Associates
35
T. Rowe Price Associates
Maryland
$4.9M +$3.48M +275,999 New
HWAM
36
Hennion & Walsh Asset Management
New Jersey
$4.5M +$302K +23,961 +10%
Bank of America
37
Bank of America
North Carolina
$4.17M +$2.64M +209,331 +822%
Rafferty Asset Management
38
Rafferty Asset Management
New York
$4.09M +$2.9M +230,573 New
Norges Bank
39
Norges Bank
Norway
$3.76M -$105K -8,301 -4%
Voloridge Investment Management
40
Voloridge Investment Management
Florida
$3.65M +$2.59M +205,834 New
BFM
41
Boothbay Fund Management
New York
$3.13M +$431K +34,253 +24%
Morgan Stanley
42
Morgan Stanley
New York
$3.02M +$980K +77,819 +84%
Bank of New York Mellon
43
Bank of New York Mellon
New York
$2.97M +$225K +17,836 +12%
PHP
44
Parkman Healthcare Partners
Connecticut
$2.8M +$1.99M +158,006 New
UBS Group
45
UBS Group
Switzerland
$2.73M +$1.85M +146,897 +2,105%
PA
46
Perceptive Advisors
New York
$2.66M +$1.89M +150,000 New
Prudential Financial
47
Prudential Financial
New Jersey
$2.07M +$4.41K +350 +0.3%
NYLIM
48
New York Life Investment Management
New York
$1.83M +$146K +11,612 +13%
Citigroup
49
Citigroup
New York
$1.82M +$1.25M +99,612 +3,366%
SSA
50
Schonfeld Strategic Advisors
New York
$1.81M -$197K -15,639 -13%
1
2
3 4 5

IMVT Hedge Fund Activity: Q4 2022 in Review

133 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q4 2022, worth a combined $980M — up 312% from $238M a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new IMVT positions and 18 closed out — a net gain of 21 holders — while 53 added to existing stakes and 28 trimmed.

The largest buyer was Logos Global Management, opening a new position worth an estimated $39.7M. The largest seller was Alpine Global Management, cutting an estimated $35.9M.

  • 133 institutional investors held Immunovant (IMVT) as of Q4 2022, up from 112 in Q3 2022.
  • Funds reported $980M of Immunovant stock for Q4 2022, up 312% quarter-over-quarter.
  • 39 funds opened new Immunovant positions in Q4 2022 and 18 closed out, a net change of +21 holders.
  • The largest Immunovant buyer in Q4 2022 was Logos Global Management, an estimated $39.7M added.
  • The largest Immunovant seller in Q4 2022 was Alpine Global Management, an estimated $35.9M sold.

Based on aggregated 13F filings for Q4 2022.